Eckert & Ziegler secures Ac-225 approval: Eckert & Ziegler stock gains 1.05 percent

Published on 10/29/2026 at 14:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GMP authorization enables routine Ac-225 production. Eckert & Ziegler stock costs EUR 13.44 on October 29, 2026 versus the Xetra close.

What changed for Eckert & Ziegler

The Actinium-225 authorization moves the company from production capability toward routine GMP manufacturing.
The company plans additional commercial-scale capacity in China after initial operations begin in early 2027.
Eckert & Ziegler is scheduled to publish its third-quarter report on November 12, 2026.

Eckert & Ziegler, DE0005659700, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) secured manufacturing authorization for Actinium-225, while its stock stood 1.05 percent above the Xetra close. The new approval turns the company's existing production process into a GMP-grade supply capability for investigational radiopharmaceutical treatments.

The authorization was announced on October 28, 2026, by EQS News. The issuer said the certification confirms compliance with Good Manufacturing Practice requirements and supports clinical and commercial programs that use Ac-225.

Supply security becomes the key angle

Eckert & Ziegler processes irradiated Radium-226 at its Braunschweig site after cyclotron-based irradiation at the Czech Academy of Sciences' Nuclear Physics Institute. The company also recovers unconverted Radium-226 for repeated use, a process designed to reduce dependence on constrained precursor inventories and improve output predictability.

The announcement adds a capacity path beyond Germany. Eckert & Ziegler's joint venture in Jintan, China, is intended to become the country's first commercial-scale Ac-225 production site, with the second phase planned after initial operations begin in early 2027. Further capacity expansion is being considered near Boston and in Germany.

Next company date

Eckert & Ziegler's next scheduled reporting date is November 12, 2026. That report will provide the next operating checkpoint for the new manufacturing platform and the wider Medical and Isotope Products businesses.

Stock position after the announcement

At Lang & Schwarz, the stock was trading at EUR 13.44 on October 29, 2026 at 2:14 p.m. CEST, up 1.05 percent versus the Xetra close of October 28, 2026 at EUR 13.30. The increase is presented as a market observation rather than a stated causal reaction to the authorization.

The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.